1.The effect of 6 weeks of treatment with inhaled budesonide on bronc-hial hyperresponsiveness and adrenal function in asthmatic patients.
Kwan Hyoung KIM ; Yong Seok OH ; Chi Hong KIM ; Soon Seong KWON ; Young Kyoon KIM ; Ki Don HAN ; Hwa Sik MOON ; Jeong Sup SONG ; Sung Hak PARK
Tuberculosis and Respiratory Diseases 1992;39(3):219-227
No abstract available.
Budesonide*
;
Humans
2.Three-month Treatment Response and Exacerbation in Chronic Obstructive Pulmonary Disease.
Jung Su LEE ; Chin Kook RHEE ; Kwang Ha YOO ; Ji Hyun LEE ; Ho Il YOON ; Tae Hyung KIM ; Woo Jin KIM ; JinHwa LEE ; Seong Yong LIM ; Tai Sun PARK ; Jae Seung LEE ; Sei Won LEE ; Sang Do LEE ; Yeon Mok OH
Journal of Korean Medical Science 2015;30(1):54-59
The aim of this study was to investigate relationships between acute exacerbation and Forced Expiratory Volume 1 second (FEV1) improvement after treatment with combined long-acting beta-agonist (LABA) and inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD). A total of 137 COPD patients were classified as responders or nonresponders according to FEV1 improvement after 3 months of LABA/ICS treatment in fourteen referral hospitals in Korea. Exacerbation occurrence in these two subgroups was compared over a period of 1 yr. Eighty of the 137 COPD patients (58.4%) were classified as responders and 57 (41.6%) as nonresponders. Acute exacerbations occurred in 25 patients (31.3%) in the responder group and in 26 patients (45.6%) in the nonresponder group (P=0.086). FEV1 improvement after LABA/ICS treatment was a significant prognostic factor for fewer acute exacerbations in a multivariate Cox proportional hazard model adjusted for age, sex, FEV1, smoking history, 6 min walk distance, body mass index, exacerbation history in the previous year, and dyspnea scale.Three-month treatment response to LABA/ICS might be a prognostic factor for the occurrence of acute exacerbation in COPD patients.
Adrenal Cortex Hormones/*therapeutic use
;
Adrenergic beta-2 Receptor Agonists/*therapeutic use
;
Bronchodilator Agents/*therapeutic use
;
Budesonide/therapeutic use
;
Drug Therapy, Combination
;
Female
;
Fluticasone/therapeutic use
;
Forced Expiratory Volume/drug effects/*physiology
;
Formoterol Fumarate/therapeutic use
;
Humans
;
Male
;
Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology
;
Recurrence
;
Republic of Korea
;
Salmeterol Xinafoate/therapeutic use
;
Smoking
;
Spirometry
;
Treatment Outcome
3.Effects of different dosage of inhaled budesonide and beclomethasone dipropionate on the cortisol concentration.
Young Seung LEE ; Soo Mi CHOI ; Ha Sook SONG ; Jong Ku KIM ; Yong Chul LEE ; Yang Keun RHEE
Korean Journal of Medicine 1993;45(6):726-735
No abstract available.
Beclomethasone*
;
Budesonide*
;
Hydrocortisone*
4.A Comparison of the Therapeutic Effects of Powder and Aerosolized Budesonide in the Treatment of Perennial Allergic Rhinitis.
Yang Gi MIN ; Hong Ju PARK ; Ji Hun MO ; Ja Bock YUN ; In Ho JUNG ; Tae Young KWON
Journal of Rhinology 1998;5(1):11-14
The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult
;
Ambulatory Care
;
Budesonide*
;
Compliance
;
Epistaxis
;
Headache
;
Humans
;
Rhinitis*
5.A Comparison of the Therapeutic Effects of Powder and Aerosolized Budesonide in the Treatment of Perennial Allergic Rhinitis.
Yang Gi MIN ; Hong Ju PARK ; Ji Hun MO ; Ja Bock YUN ; In Ho JUNG ; Tae Young KWON
Journal of Rhinology 1998;5(1):11-14
The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult
;
Ambulatory Care
;
Budesonide*
;
Compliance
;
Epistaxis
;
Headache
;
Humans
;
Rhinitis*
6.The Effect of Nebulized Budesonide and Intreamuscular Dexamethasone in Patients with Moderate Group.
Su Jin LEE ; Hyun Ju LEE ; Su Ja HWANG ; Eun Ae PARK ; Ho Seong KIM ; Seung Joo LEE
Pediatric Allergy and Respiratory Disease 1998;8(2):248-255
PURPOSE: To evaluate the effect f nebulized budensonide and intramuscular dexamethasone in relieving laryngeal obstruction of croup. METHODS: Forty patients with moderate croup (croup scores of 3 to 7 out of 17) were randomly assigned to budesonide group [1 mg(2 ml) of nebulized budesonide, N=15], dexamethasone group [intramuscular dexamethasone(0.5 mg/kg) and nebulized saline, N=10] and control group(2 ml of nebulized saline, N=15). The changes of croup scores, heart rate, respiratory rate, and arterial oxygen saturation(SaO2) were observed at post-treatment of 2, 24, 36 and 48 hours. The duration of admission and the rates of improvement to the croup score of < or = 1 at the post-treatments were compared. RESULTS: Croup scores at 12, 24 and 36 hours post treatments were 1.7+/-0.8, 1.1+/-0.7 and 0.8+/-0.7 in budensonide group and 2.2+/-0.7, 1.2+/-0.8 and 1.0+/-0.5 in dexamethasone group respectively, which were significantly lower rate, and SaO2 were not significantly different among the three groups. Improved rates to croup score of <1 in budesonide group at post-treatments of 12, 24, and 36 jpirs were 53%, 73% and 87%, which were significantly higher than 0%, 13%, and 47% in control group (p<0.05). Improved rate to croup score of < or = 1 in dexamethasone group was 60^ which was significantly hgier than 13% in control group only at post-treatment of 24 hours (p<0.05). CONCLUSION: Nebulized budesonide and intramusculan dexamethasone are both effective in reducing obstructive symptoms in patients with moderate croup. The effect of nebulized budesonide was more rapid than that of intramuscular dexamethasone.
Budesonide*
;
Croup
;
Dexamethasone*
;
Heart Rate
;
Humans
;
Oxygen
;
Respiratory Rate
7.Effect of Inhaled Corticosteroid and Leukotriene Receptor Antagonist in Cough-variant Asthma Patients under Five Years of Age.
Pediatric Allergy and Respiratory Disease 2005;15(3):263-269
PURPOSE: Cough-variant asthma (CVA) is a common cause of chronic cough in young children. Some children who have CVA eventually develop classic asthma. We evaluated the effect of inhaled corticosteroid and leukotriene receptor antagonist in young children who are suspected of having CVA. METHODS: Thirty-seven cough-variant asthma patients younger than 5-years-old were enrolled in this study. Fifteen were treated with pulmicort nebulization (500 micorgram, bid) for 4 weeks (Group A). Fourteen were treated with leukotriene receptor antagonist (Singulair, 4 mg) for 4 weeks (Group B). Eleven were treated with intermittent short-acting beta2-agonist nebulization (Group C). We evaluated the mean change of symptom score in night cough and sleep disturbance. RESULTS: There were no differences in age, sex, total IgE, total eosinophil count or duration of cough among the three groups. Group A and B showed significant improvement of night cough and sleep disturbance after treatment. (P< 0.05) In Group A and B, night cough was significantly improved after treatment more than in control. (P< 0.05) But improvements in sleep disturbance didn't have any signigicant differences between the three groups. (P= 1.0) CONCLUSION: Inhaled corticosteroid and leukotriene receptor antagonist are effective to control chronic cough in CVA children younger than 5-years-old.
Asthma*
;
Budesonide
;
Child
;
Cough
;
Eosinophils
;
Humans
;
Immunoglobulin E
;
Receptors, Leukotriene*
8.Effect of Nebulized Steroid (Budesonide) and Parenteral Steroid (Dexamethasone) on Children with Croup.
Seon Mee AHN ; Jung Ae SOHN ; Chul Zoo JUNG ; Dong Jin LEE ; Young Hwan LEE ; Yong Hoon PARK
Journal of the Korean Pediatric Society 1997;40(4):265-276
PURPOSE: This prospective study was conducted to evaulate the effect of nebulized steroid (budesonide) and parenteral steroid (dexamethasone) on chidren with croup. METHODS: Twenty nine infants and children (6months-5years of age) admitted to hospital with croup were randomly assigned to receive either 1mg (4ml) of nebulized budesonide (17 patients) or 0.6mg/kg intramuscular injection of dexamethasone sodium phosphate (12 patients). Total croup score, heart rate and respiratory rate of patients were assessed on admission, 30 minutes, 2 hours, 6 hours, 12 hours and 24 hours after treatment, respectively. RESULTS: 1) In total cases, total croup score were significantly decreased at 30 minutes after treatment in the group treated with nebulized budesonide (p<0.01) but at 2 hours after treatmetn in the group treated with dexamethasone (p<0.05). 2) In mild cases (total croup score<5), total croup score were significantly decreased at 2 hours after treatment in the both group (p<0.05). 3) In moderate to severe cases (total croup score> or =5), total croup score were significantly decreased at 30 minutes after treatment in the group treated with nebulized budesonide (p<0.05). But in group treated with dexamethasone, there were no statistical significance because of small cases. 4) Respiratory rate was decreased after treatment in the both group, but significantly decreased at 2 hours after treatment in the group treated with dexamethasone (p<0.05). 5) Heart rate was decreased after treatment in the both group, but significantly decreased at 30 minutes after treatment in the group treated with dexamethasone (p<0.05). 6) There were no significant side effects in the both group. CONCLUSIONS: We conclude that both nebulized budesonide and parenteral dexamethasone were effective in treatment of croup, and that nebulized budesonide leads to more rapid clinical improvement in children with croup, especially moderate to severe one.
Budesonide
;
Child*
;
Croup*
;
Dexamethasone
;
Heart Rate
;
Humans
;
Infant
;
Injections, Intramuscular
;
Prospective Studies
;
Respiratory Rate
;
Sodium
9.Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy.
Young Min YE ; Sang Ha KIM ; Gyu Young HUR ; Joo Hee KIM ; Jung Won PARK ; Jae Jeong SHIM ; Ki Suck JUNG ; Hyun Young LEE ; Hae Sim PARK
Allergy, Asthma & Immunology Research 2015;7(5):440-448
PURPOSE: There have been few reports regarding the efficacy of antiasthmatics in older patients. To compare the efficacy of the addition of montelukast to low-dose inhaled budesonide (MON-400BUD) versus increasing the dose of inhaled steroid (800BUD) on asthma control in older asthmatics. METHODS: A randomized, open-label, parallel-designed trial was conducted for 12 weeks. The primary endpoint was the rate of patients who reached "well-controlled asthma status" after the 12-week treatment period. Additionally, asthma exacerbations, sputum inflammatory cells, asthma control test (ACT) and physical functioning scale (PFS), and adverse reactions were monitored. RESULTS: Twenty-four (36.9%) and 22 (34.9%) subjects in the MON-400BUD (n=65) and 800BUD (n=63) groups had well-controlled asthma at the end of the study, respectively. The numbers of asthma exacerbations requiring oral corticosteroid treatment (20 vs 9, respectively, P=0.036) and the development of sore throat (22 vs 11, respectively, P=0.045) were significantly higher in the 800BUD group than in the MON-400BUD group. Body mass index and changes in ACT, FEV1%, 6-min walk distance and PFS from baseline were all significant determinants for distinguishing subjects with well-controlled and partly controlled asthma from those with uncontrolled asthma (P<0.05) at the end of the study. CONCLUSIONS: The efficacy of 12-week treatment with MON-400BUD in older asthmatics was comparable to that of 800BUD on asthma control but associated with reduced frequency of asthma exacerbations requiring oral steroids and sore throat events. Changes in ACT and PFS can be useful predictors of asthma control status in older patients.
Anti-Asthmatic Agents
;
Asthma
;
Body Mass Index
;
Budesonide
;
Humans
;
Motor Activity
;
Pharyngitis
;
Sputum
;
Steroids
10.A Case of Atopic Dermatitis with Egg and Budesonide Hypersensitivity.
Hyun Wook KIM ; Gyeong Il KIM ; Chun Wook PARK ; Cheol Heon LEE
Korean Journal of Dermatology 2001;39(11):1286-1289
The egg is one of the most common food allergens, and immunologic reactivity to egg antigens may be an early marker of atopic disorders. Budesonide is a synthetic non-halogenated corticosteroid with 16 , 17 -butylidene dioxy portion, and it is one of the common causes of corticosteroid allergy together with tixocortol pivalate and hydrocortisone butyrate. The patient was a 12 year old female. She had developed atopic dermatitis mainly on the face since she was 1 year old. She applied budesonide cream for treating atopic dermatitis in our dermatologic clinic, but her facial lesion was aggravated. On past medical history, she had been suffered from an egg allergy since 1-year-old, and she was accidentally exposed to egg and developed large pruritic erythematous patch on entire body. This case could be considered as atopic dermatitis with egg and budesonide hypersensitivity on the basis of the clinical features and prick test, MAST, open food challenge and patch test.
Allergens
;
Budesonide*
;
Butyrates
;
Child
;
Dermatitis, Atopic*
;
Egg Hypersensitivity
;
Female
;
Humans
;
Hydrocortisone
;
Hypersensitivity*
;
Ovum*
;
Patch Tests